05/08/2020 7:02 am Welcome to isteroids.com - BLOG

Tuesday 06, Apr 2010

  Teriparatide superior to Alendronate for treating Osteoporosis

Posted By
Pin it Share on Tumblr

The injectable form of Teriparatide, Forteo, is superior to oral Alendronate, Fosamax, in a head-to-head comparison when it comes to improving bone mineral density (BMD) by as much as twice.

Teriparatide promotes greater increases in bone-mineral density at the spine and hip, as per Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues.Teriparatide superior to Alendronate for treating Osteoporosis

Philip N. Sambrook, M.D., of the University of Sydney, said that Saag’s findings suggest that teriparatide is a superior drug for treating steroid-induced Osteoporosis.

Friday 30, Oct 2009

  Teriparatide effective than Alendronate for steroid-induced osteoporosis

Posted By
Pin it Share on Tumblr

Teriparatide effective than Alendronate for steroid-induced osteoporosisInjectable teriparatide (foreto) increases BMD (bone mineral density) by as much as two percent when compared to oral alendronate (fosamax) in a head-to-head comparison, according to a recent study.

It was remarked by Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues, that teriparatide was found in a relationship with enhanced improvements in the level of bone mineral density at the spine and hip.

Philip N. Sambrook, M.D., of the University of Sydney, said that teriparatide can prove to be a breakthrough option as a potential first-line therapy for steroid-Induced Osteoporosis as per the findings of Saag and his colleagues.

For informational purposes, teriparatide is currently approved for men and postmenopausal women with osteoporosis suffering from the high risk of fractures.

Tuesday 16, Jun 2009

  Teriparatide Better than Alendronate in Steroid-Induced Osteoporosis

Posted By
Pin it Share on Tumblr

Teriparatide Better than Alendronate in Steroid-Induced OsteoporosisInvestigators have found that injectable teriparatide (Forteo) increase bone-mineral density (BMD) by as much as two times as compared to oral alendronate (Fosamax) in a head-to-head comparison.

Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues, remarked that teriparatide was found to be associated with greater increases in bone-mineral density at the spine and hip.

Philip N. Sambrook, M.D., of the University of Sydney, remarked that teriparatide is considered as a potential first-line therapy for steroid-Induced Osteoporosis as per the findings of Saag and his colleagues.

It is worthwhile to note that teriparatide is presently approved only for men and postmenopausal women with osteoporosis, who suffer from the high risk of fractures.